Patterns of progression in oligometastatic hormone receptor positive breast cancer after first-line systemic treatment at the metastatic stage

被引：0
|
作者：
Lacaze, Jean Louis
De Maio, Eleonora
Chaltiel, Leonor
Cabarrou, Bastien
Mounat, Thibaut Cassou
Chira, Ciprian
Glemarec, Gauthier
Massabeau, Carole
Nicolai, Vincent
Selmes, Gabrielle
机构：
[1] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[2] IUCT Oncopole, Toulouse, France
[3] IUCT Oncopole, Inst Claudius Regaud, Dept Chirurg Oncol, Toulouse, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13054
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
    Peter A. Kaufman
    Sara A. Hurvitz
    Joyce O’Shaughnessy
    Ginny Mason
    Denise A. Yardley
    Adam M. Brufsky
    Hope S. Rugo
    Melody Cobleigh
    Sandra M. Swain
    Debu Tripathy
    Anne Morris
    Vincent Antao
    Haocheng Li
    Mohammad Jahanzeb
    Breast Cancer Research and Treatment, 2021, 188 : 179 - 190
  • [32] Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
    Kaufman, Peter A.
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Mason, Ginny
    Yardley, Denise A.
    Brufsky, Adam M.
    Rugo, Hope S.
    Cobleigh, Melody
    Swain, Sandra M.
    Tripathy, Debu
    Morris, Anne
    Antao, Vincent
    Li, Haocheng
    Jahanzeb, Mohammad
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 179 - 190
  • [33] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply
    Ellis, Matthew J.
    Robertson, John F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1960 - +
  • [34] First-line systemic therapy for metastatic breast cancer and management of pleural effusion
    Perrone, F
    Carlomagno, C
    DePlacido, S
    Lauria, R
    Morabito, A
    Bianco, AR
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 1033 - 1043
  • [35] Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).
    Lee, Elizabeth K.
    Teply, Benjamin A.
    Maughan, Benjamin Louis
    Carducci, Michael Anthony
    Antonarakis, Emmanuel S.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy
    Miyawaki, Taichi
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Notsu, Akifumi
    Mori, Keita
    Harada, Hideyuki
    Endo, Masahiro
    Ohde, Yasuhisa
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    CANCER SCIENCE, 2021, 112 (01) : 359 - 368
  • [37] First-Line Chemotherapy for Metastatic Breast Cancer
    Telli, Melinda L.
    Carlson, Robert W.
    CLINICAL BREAST CANCER, 2009, 9 : S66 - S72
  • [38] Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
    Huang, Xiaoting
    Weng, Xiuhua
    Lin, Shen
    Liu, Yiwei
    Luo, Shaohong
    Wang, Hang
    Ming, Wai-kit
    Huang, Pinfang
    BMJ OPEN, 2020, 10 (08):
  • [39] An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)
    Ahlgren, P.
    Thirlwell, M.
    O'Regan, R.
    Mormont, C.
    Levesque, L.
    Gaspo, R.
    Woloj, M.
    Bello, A.
    Martell, B.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] The metastatic receptor status impact on first-line treatment plans and clinical outcomes for recurrent metastatic breast cancer
    Pannell, T.
    CLINICAL & EXPERIMENTAL METASTASIS, 2019, 36 (02) : 150 - 151
12345